Vectus Biosystems Ltd - Asset Resilience Ratio

Latest as of December 2023: 2.18%

Vectus Biosystems Ltd (VBS) has an Asset Resilience Ratio of 2.18% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VBS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$70.00K
≈ $49.53K USD Cash + Short-term Investments

Total Assets

AU$3.21 Million
≈ $2.27 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2020)

This chart shows how Vectus Biosystems Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Vectus Biosystems Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Vectus Biosystems Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read VBS current and long-term liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$70.00K 2.18%
Total Liquid Assets AU$70.00K 2.18%

Asset Resilience Insights

  • Limited Liquidity: Vectus Biosystems Ltd maintains only 2.18% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Vectus Biosystems Ltd Industry Peers by Asset Resilience Ratio

Compare Vectus Biosystems Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Abivax SA
PA:ABVX
Biotechnology 2.58%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%
Pulike Biological Engineering
SHG:603566
Biotechnology 17.82%
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Biotechnology 14.00%
NEWRON PHARMACEUT. EO-20
XETRA:NP5
Biotechnology 41.67%
Upstream Bio, Inc.
NASDAQ:UPB
Biotechnology 64.70%

Annual Asset Resilience Ratio for Vectus Biosystems Ltd (2013–2020)

The table below shows the annual Asset Resilience Ratio data for Vectus Biosystems Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-06-30 90.60% AU$2.72 Million
≈ $1.92 Million
AU$3.00 Million
≈ $2.12 Million
+4.48pp
2016-06-30 86.11% AU$4.03 Million
≈ $2.85 Million
AU$4.68 Million
≈ $3.31 Million
+85.82pp
2015-06-30 0.29% AU$33.99K
≈ $24.05K
AU$11.73 Million
≈ $8.30 Million
-77.53pp
2013-06-30 77.82% AU$1.16 Million
≈ $821.49K
AU$1.49 Million
≈ $1.06 Million
--
pp = percentage points

About Vectus Biosystems Ltd

AU:VBS Australia Biotechnology
Market Cap
$5.10 Million
AU$7.21 Million AUD
Market Cap Rank
#28645 Global
#1532 in Australia
Share Price
AU$0.14
Change (1 day)
+0.00%
52-Week Range
AU$0.06 - AU$0.44
All Time High
AU$2.00
About

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more